Company / Current Liabilities per Share
Regeneron Pharmaceuticals Current Liabilities per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities per Share
$38.42
FY2025
5-year range
$27.29 / $38.42
FY2021-FY2025
Trend
+10.6%
vs FY2024
Sector context
#6 of 210
Health Care
What the data says
Among 210 Health Care companies, Regeneron Pharmaceuticals is in the bottom 3% for current liabilities per share. Current Liabilities per Share has increased for 3 consecutive years, from $27.29 in FY2022 to $38.42 in FY2025.
Based on SEC 10-K filings.
38.42 in FY2025 with a 5-year CAGR of +10.3%. Top quartile in the Health Care sector.
Increased from $30.51 to $38.42 over the past 2 years.
Health Care sector context is included.
Current Liabilities per Share over time
Growth rates
- 3-Year CAGR
- +12.1%
- 5-Year CAGR
- +10.3%
- 10-Year CAGR
- -
Sector benchmark
+61.5% above sector average
Key checks
Key Insights
- Regeneron Pharmaceuticals's current liabilities per share has grown for 3 consecutive years.
- In FY2025, current liabilities per share increased 10.6% year-over-year.
- Ranks #6 out of 210 companies in the Health Care sector.
- Lowest current liabilities per share in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Liabilities per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $38.42 | +10.6% |
| FY2024 | $34.75 | +13.9% |
| FY2023 | $30.51 | +11.8% |
| FY2022 | $27.29 | -20.5% |
| FY2021 | $34.32 | +46.0% |
| FY2020 | $23.50 | +29.9% |
| FY2019 | $18.09 | +45.8% |
| FY2018 | $12.41 | +25.9% |
| FY2017 | $9.85 | -10.0% |
| FY2016 | $10.95 | +50.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026